Efficacy and Safety of Target Combined Chemotherapy in Advanced Gastric Cancer: a Meta-analysis and System Review

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2016 Sep 17

PMID 27633381

Citations 12

Authors

Kun Zou

Shuailong Yang

Liang Zheng

Chaogang Yang

Bin Xiong

Affiliations

Soon will be listed here.

Abstract

Background: The aim of our meta-analysis is to assess the efficacy and safety of the target combined chemotherapy for the patients with unresectable advanced or recurrent gastric cancer.

Methods: In accordance with the standard meta-analysis procedures, the patients included in our study were with unresectable advanced or recurrent gastric cancer and allocated randomly to receive target combined chemotherapy or the traditional chemotherapy. The search was applied to PubMed, EMBASE, Science Citation Index Expanded, Cocran's library (from inception to February 2016). All analyses were performed by STATA 12.0, with the odds ratio, hazard ratio, and 95 % confidence interval as the effect measures.

Results: Fourteen studies were included in this meta-analysis. A total of 5067 patients with advanced gastric cancer were divided into two arms: traditional chemotherapy arm and target combined chemotherapy arm. A significant improvement for overall survival (hazard ratio was 0.89, 95 % confidence interval: 0.83-0.95) and overall response rate (odds ratio was 1.44, 95 % confidence interval: 1.15-1.81) was observed, but no significant difference was found for progression-free survival (hazard ratio was 0.89, 95 % confidence interval: 0.77-1.00) in the target combined chemotherapy arm. In subgroup analysis, increasing benefits regarding overall survival and progression-free survival were found in anti epidermal growth factor receptor target drugs for selected patients subgroup and anti vascular endothelial growth factor receptor target drugs for unselected patients subgroup, but not in anti epidermal growth factor receptor target drugs for unselected patients subgroup. Besides, some adverse events were increased in the target combined chemotherapy arm.

Conclusions: The target combined chemotherapy represented a better overall survival benefit and treatment efficiency and higher incidence of some grade 3-4 adverse events than the traditional chemotherapy for patients with unresectable advanced or recurrence gastric cancer. The anti vascular endothelial growth factor receptor drugs can improve the efficacy in the whole patients with unresectable advanced or recurrence gastric cancer and the anti epidermal growth factor receptor target drugs can only improve the efficacy in the epidermal growth factor receptor positive patients.

Citing Articles

Resistance Management for Cancer: Lessons from Farmers.

Seyedi S, Harris V, Kapsetaki S, Narayanan S, Saha D, Compton Z Cancer Res. 2024; 84(22):3715-3727.

PMID: 39356625 PMC: 11565176. DOI: 10.1158/0008-5472.CAN-23-3374.

Efficacy and safety of a novel TKI (anlotinib) for the treatment of advanced digestive system neoplasms: a systematic review and meta-analysis.

Zhou C, Wang W, Mu Y, Meng M Front Immunol. 2024; 15:1393404.

PMID: 39206183 PMC: 11349560. DOI: 10.3389/fimmu.2024.1393404.

Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer.

Jiang Y, Li W, Qiu Y, Yue M World J Gastrointest Oncol. 2024; 16(6):2318-2334.

PMID: 38994153 PMC: 11236256. DOI: 10.4251/wjgo.v16.i6.2318.

Identification and Validation of a m5C RNA Modification-Related Gene Signature for Predicting Prognosis and Immunotherapeutic Efficiency of Gastric Cancer.

Song L, Wang S, Li Q, Lu Y, Yang R, Feng X J Oncol. 2023; 2023:9931419.

PMID: 36936373 PMC: 10017215. DOI: 10.1155/2023/9931419.

The efficacy of targeted therapy combined with radiotherapy and temozolomide-based chemotherapy in the treatment of glioma: A systemic review and meta-analysis of phase II/III randomized controlled trials.

Ma Y, Wang Y, Nie C, Lin Y Front Oncol. 2023; 13:1082539.

PMID: 36776303 PMC: 9909217. DOI: 10.3389/fonc.2023.1082539.

References

Sawaki A, Ohashi Y, Omuro Y, Satoh T, Hamamoto Y, Boku N . Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer. 2011; 15(3):313-22. PMC: 3390686. DOI: 10.1007/s10120-011-0118-1. View

Hecht J, Bang Y, Qin S, Chung H, Xu J, Park J . Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2015; 34(5):443-51. DOI: 10.1200/JCO.2015.62.6598. View

Clemente G, Chiarla C, Giovannini I, De Rose A, Astone A, Barone C . Gas in portal circulation and pneumatosis cystoides intestinalis during chemotherapy for advanced rectal cancer. Curr Med Res Opin. 2010; 26(3):707-11. DOI: 10.1185/03007990903566798. View

Kawaguchi T, Komatsu S, Ichikawa D, Kubota T, Okamoto K, Konishi H . Clinical significance of chemotherapy for geriatric patients with advanced or recurrent gastric cancer. Mol Clin Oncol. 2014; 3(1):83-88. PMC: 4251132. DOI: 10.3892/mco.2014.451. View

Satoh T, Lee K, Rha S, Sasaki Y, Park S, Komatsu Y . Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer. 2014; 18(4):824-32. PMC: 4572054. DOI: 10.1007/s10120-014-0420-9. View

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

Luo H, Han L, Jiang Y . Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer. Asian Pac J Cancer Prev. 2014; 15(13):5343-8. DOI: 10.7314/apjcp.2014.15.13.5343. View

Wilke H, Muro K, Van Cutsem E, Oh S, Bodoky G, Shimada Y . Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15(11):1224-35. DOI: 10.1016/S1470-2045(14)70420-6. View

Muro K, Oh S, Shimada Y, Lee K, Yen C, Chao Y . Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. J Gastroenterol Hepatol. 2015; 31(3):581-9. DOI: 10.1111/jgh.13153. View

10.

Waddell T, Chau I, Cunningham D, Gonzalez D, Okines A, Frances A . Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013; 14(6):481-9. PMC: 3669518. DOI: 10.1016/S1470-2045(13)70096-2. View

11.

Koizumi W, Yamaguchi K, Hosaka H, Takinishi Y, Nakayama N, Hara T . Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer. Br J Cancer. 2013; 109(8):2079-86. PMC: 3798959. DOI: 10.1038/bjc.2013.555. View

12.

Wagner A, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J . Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010; (3):CD004064. DOI: 10.1002/14651858.CD004064.pub3. View

13.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

14.

Kurokawa Y, Sugimoto N, Miwa H, Tsuda M, Nishina S, Okuda H . Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer. 2014; 110(5):1163-8. PMC: 3950868. DOI: 10.1038/bjc.2014.18. View

15.

Rao S, Starling N, Cunningham D, Sumpter K, Gilligan D, Ruhstaller T . Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol. 2010; 21(11):2213-2219. DOI: 10.1093/annonc/mdq247. View

16.

Ohtsu A, Shah M, Van Cutsem E, Rha S, Sawaki A, Park S . Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011; 29(30):3968-76. DOI: 10.1200/JCO.2011.36.2236. View

17.

Fuchs C, Tomasek J, Yong C, Dumitru F, Passalacqua R, Goswami C . Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2013; 383(9911):31-39. DOI: 10.1016/S0140-6736(13)61719-5. View

18.

Ychou M, Boige V, Pignon J, Conroy T, Bouche O, Lebreton G . Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011; 29(13):1715-21. DOI: 10.1200/JCO.2010.33.0597. View

19.

Kim M, Lee H, Lee H, Jeon Y, Yang H, Kim W . EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology. 2008; 52(6):738-46. DOI: 10.1111/j.1365-2559.2008.03021.x. View

20.

Lieto E, Ferraraccio F, Orditura M, Castellano P, La Mura A, Pinto M . Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2007; 15(1):69-79. DOI: 10.1245/s10434-007-9596-0. View